Navigation Links
Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Date:12/27/2007

haritable.org/pdf/contribute.pdf" target="_new">http://www.schwabcharitable.org/pdf/contribute.pdf

1-800-746-6137

About the Center for Research on Early Detection and Cure of Ovarian Cancer at the University of Pennsylvania

The Center for Research on Early Detection and Cure of Ovarian Cancer, directed by Dr. George Coukos, is a newly founded Research Center at the University of Pennsylvania. The Center comprises several full time translational and clinical scientists whose focus is to identify new detection methods, develop new therapies, and ultimately prolong and improve the quality of life for women with ovarian cancer.

Recent discoveries at the Center include the beneficial impact of immune response in advanced ovarian cancer; the contribution of inflammatory cells to the tumor vasculature; the role of tumor vasculature and tumor microenvironment in controlling the outcome of antitumor immune response and immune therapy; the identification of novel proteins expressed in ovarian cancer vasculature that can be targeted for early detection and therapy; and the identification of several gene alterations in ovarian cancer including miRNA genes.

The clinical research activities of the Center focus on developing individualized therapy approaches to patients with ovarian cancer, combining surgery and conventional therapy with novel immune therapies. A number of novel immune cellular therapeutic tools are under development in collaboration with the Cell and Vaccine Production Facility at the Abramson Cancer Center, directed by Drs. Carl June and Bruce Levine.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those project
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily stressors ... explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at ... Resort Maui, the island’s only Forbes Five Star resort and Travel + Leisure’s No. ...
(Date:9/4/2015)... ... ... for a quick and convenient way to produce a hot remedy for colds. The K ... and simple way to brew a hot cup of cold remedy when desired. In doing ... comfort and health. The invention features a novel design that is lightweight, compact and portable. ...
(Date:9/4/2015)... Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... Program was ranked number 9 nationwide by Doximity. Faculty, residents and staff ... we take great pride in the quality of our ophthalmology residency program. Our faculty ...
(Date:9/4/2015)... ... September 04, 2015 , ... Having access to a doctor ... to an increasing amount of unnecessary emergency room visits which affects hospitals’ abilities to ... country’s health bill. Fortunately, a solution to alleviate this problem has recently presented itself, ...
(Date:9/4/2015)... New York, NY (PRWEB) , ... September 04, 2015 , ... ... 400 meters qualifying heat, and followed up with victory in the men’s 400 meters ... Caribbean (NACAC) Senior Track and Field Championships in San Jose, Costa Rica in August ...
Breaking Medicine News(10 mins):Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3
... INDIANAPOLIS, Nov. 16 Standard Management,Corporation ("Standard ... an Indianapolis-based company, provides through Universal Healthcare,Company, ... long-term care,and infusion therapy sector of the ... definitive stock purchase agreement to sell its ...
... Calls upon State Regulators to Impose Stiffer Penalties, ... License for Lying to State Investigators, CLAREMONT, ... yesterday filed a class action lawsuit against Health ... practice of,retroactively canceling health insurance policies has needlessly ...
... Ohio, Nov. 16 Robbins & Myers, Inc.,(NYSE: ... the Bear Stearns,3rd Annual Commodities and Capital Goods Conference ... Wallace, President and Chief Executive Officer,and Christopher M. Hix, ... the Company. The Company,s presentation is set for ...
... factors at six sites nationwide , FRIDAY, Nov. ... at the genetic and environmental factors that may cause ... enrolling 2,700 children and their families from six areas ... Early Development -- which researchers called the largest of ...
... Four Small Holes Between Ribs ... After 1 1/2 Days, TYLER, Texas, Nov. 16 ... is the first in east,Texas to benefit from a heart ... System. Mr. Roden was released from the,hospital just 1 1/2 ...
... to the,recently released follow-up study to the ... the August issue of the,Journal of the ... children and young people with AD/HD who ... with behavioral management and,educational adaptations fared better ...
Cached Medicine News:Health News:Standard Management Signs Stock and Real Estate Purchase Agreement 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 2Health News:Health Net Hit With Class Action Alleging Unfair Business Practices Over Retroactive Cancellations of Health Insurance Policies 3Health News:Major U.S. Autism Study Gets Under Way 2Health News:Video: Patient at Mother Frances Receives Heart Bypass Without Opening Chest 2
... Ventilates and removes chemical fumes, ... exhaust. Bonded charcoal filters remove ... ensure safe exhaust flow speed ... access opening. Includes air speed ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... fume hood is the same ... includes a flat internal baffle ... shell. The baffle slopes forward, ... flow to sweep the deck ...
This fume hood features a one-piece shell molded of polyethylene with a clear acrylic panel that slides on inside tracks. It can be set in an open, closed or intermediate position....
Medicine Products: